Published online before print June 24, 2002, doi: 10.1161/01.CIR.0000022664.21832.5D
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2002;106:304.)
© 2002 American Heart Association, Inc.
Clinical Investigation and Reports |
Heritability of Coronary Artery Calcium Quantity Measured by Electron Beam Computed Tomography in Asymptomatic Adults
From the Department of Epidemiology, University of Michigan, Ann Arbor, Mich (P.A.P., L.F.B., J.S.C.); Division of Hypertension, Department of Internal Medicine (S.T.T.), and Department of Diagnostic Radiology (P.F.S.), Mayo Clinic and Foundation, Rochester, Minn; Gene and Drug Discovery Center, Windber Research Institute, Windber, Pa (D.L.E.); and Human Genetics Center and Institute of Molecular Medicine, University of Texas, Houston Health Science Center, Houston (E.B.).
Correspondence to Patricia A. Peyser, University of Michigan, Department of Epidemiology, 109 Observatory, Ann Arbor, MI 48109. E-mail ppeyser{at}umich.edu
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background— Electron beam computed tomography is an accurate, noninvasive method to detect and quantify coronary artery calcification (CAC), a marker of subclinical and clinical coronary artery atherosclerosis. CAC quantity predicts future coronary artery disease end points in asymptomatic adults, but measured risk factors explain less than half the variability in CAC quantity. Although several candidate genes for CAC have been identified, the relative importance of genetic influences on CAC quantity has not been assessed in asymptomatic adults in a community.
Methods and Results— We quantified the relative contributions of measured risk factors and genetic influences on CAC quantity measured by electron beam computed tomography in 698 asymptomatic white adults from 302 families. Before adjusting for any risk factors, 43.5% of the variation in CAC quantity was attributable to genetic factors (P=0.0007). Independent predictors of CAC quantity were identified with stepwise linear regression. After adjusting for these risk factors, including age, sex, fasting glucose level, systolic blood pressure, pack-years of smoking, and LDL cholesterol, 41.8% of the residual variation in CAC quantity was attributable to genetic factors (P=0.0003).
Conclusions— These results demonstrate the importance of genetic factors in subclinical coronary atherosclerosis variation as measured by CAC quantity. The presence of genetic effects suggests that unknown genes that influence CAC quantity are yet to be identified.
Key Words: genetics • calcium • atherosclerosis • imaging • epidemiology
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Atherosclerosis, the major cause of coronary artery disease (CAD), is influenced by a complex interplay among numerous environmental and genetic factors.1 Familial aggregation of CAD has been recognized for almost 100 years, and many established CAD risk factors have a genetic basis.2 The increased risk of CAD associated with a family history of disease even after controlling for these risk factors, however, suggests that numerous genetic factors underlying disease susceptibility are yet to be identified.
A major limitation of the use of CAD events as study end points to identify susceptibility genes is substantial disease misclassification, because many individuals with coronary atherosclerosis are asymptomatic. One half of all sudden coronary deaths and first myocardial infarctions occur in persons without previous symptoms.3
Coronary artery calcification (CAC), a marker of atherosclerosis, can be quantified noninvasively and accurately by electron beam computed tomography (EBCT).4 A direct relationship exists between CAC and both histological and in vivo intravascular ultrasound measures of atherosclerotic plaque.5 CAC quantity is an independent predictor of angiographically defined CAD after controlling for established CAD risk factors,6,7 and CAC predicts future CAD end points in asymptomatic and symptomatic adults.8,9 Many established CAD risk factors, such as male sex, older age, smoking, abnormal lipid levels, high blood pressure, and ponderosity are related to CAC quantity.7,10–13 Much variation in CAC quantity, however, remains unexplained after accounting for these factors. The purpose of the current study was to assess the overall genetic contribution (ie, heritability) to CAC quantity measured by EBCT in asymptomatic adults from the community.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Sample
The Epidemiology of Coronary Artery Calcification (ECAC) Study is an ongoing community-based study of the pathogenesis of CAC in Rochester, Minn.11,14 Participants in the ECAC Study are not self or physician referred and do not have a history of previous bypass surgery, angioplasty, or other coronary surgery. ECAC Study participants were recruited from the community-based Rochester Family Heart Study.15,16
Between December 1990 and May 1998, 787 participants in the ECAC study who were at least 45 years of age were examined for CAC with EBCT. Of these 787 participants, we excluded 76 participants because they were nonwhites (n=4), had a history of myocardial infarction and/or stroke (n=24), or had missing CAC (n=11) or incomplete risk factor (n=37) data. Thirteen participants were also excluded because LDL cholesterol could not be calculated because their triglyceride levels were >400 mg/dL. The final study group consisted of 698 (360 women) asymptomatic, nonreferred participants at least 45 years of age from 302 families. Most individuals were a sibling, spouse, parent, or offspring of another individual in the study. These different relationships allowed comparisons between genetically related and unrelated individuals. All participants gave written informed consent. The Mayo Clinic and University of Michigan Institutional Review Boards approved the study protocols and process for obtaining informed consent.
Measures
Participants reported current medication use, education, history of smoking, and physician-diagnosed hypertension, myocardial infarction, stroke, or diabetes. Standard enzymatic methods were used to measure total cholesterol, HDL cholesterol, and triglycerides after overnight fasting.15 LDL cholesterol was calculated with the Friedwald equation.17 Plasma glucose was measured by the glucose oxidase method after overnight fasting. Body mass index (kg/m2) and waist-to-hip ratio were calculated.
Resting systolic blood pressure (SBP) and diastolic blood pressure (DBP) levels were measured in the right arm with a random-zero sphygmomanometer (Hawksley and Sons). Three measures at least 2 minutes apart were taken and the average of the second and third measurements was used. Participants were considered hypertensive if the average SBP was 
140 mm Hg and/or the average DBP was 90 mm Hg, or if they reported a prior diagnosis of and treatment for hypertension and were currently using antihypertensive medications. Participants were considered diabetic if they were using insulin or oral hypoglycemic agents or if they reported a physician diagnosis of diabetes but were not currently taking a pharmacological agent to control their high glucose levels.
The Framingham risk equation was used to estimate the 10-year probability of coronary heart disease on the basis of the participant’s sex, age, SBP, total cholesterol/HDL cholesterol ratio, history of cigarette smoking in the past year, and diabetes status.18 Measurements of left ventricular hypertrophy were not included in the risk equations because they were not available.
CAC was measured with an Imatron C-100 or C-150 EBCT scanner (Imatron Inc). A scan run consisted of 40 contiguous 3-mm-thick tomographic slices from the root of the aorta to the apex of the heart. Scan time was 100 ms per tomogram. Electrocardiographic gating was used and all images were triggered at end-diastole during 2 to 4 breath-holds.
A radiological technologist scored the tomograms with an automated scoring system.19 CAC was defined as a hyperattenuating focus within 5 mm of the arterial midline and at least 4 adjacent pixels in size (ie, 1.04 mm2), with CT number above 130 HU throughout the focus. An experienced radiologist inspected the technical quality and scoring accuracy of each tomogram and interpreted their findings. Quantity of CAC was defined as the CAC score developed by Agatston and coworkers.20 In the analyses described below, we used the natural logarithmic transformation of CAC score+1 to reduce skewness.
Statistics
A generalized estimating equations approach, assuming an identity link and allowing for correlation within families, was used to investigate associations between risk factors and log (CAC score+1).21 All statistical tests for associations were 2-sided, and P<0.05 was considered statistically significant. Two linear regression models were fit to predict log (CAC score+1). The first model included age and sex as predictors. The most efficient model of independent predictors of log (CAC score+1) was identified with the use of stepwise linear regression. This second model included age, sex, fasting glucose level, SBP, log (pack-years+1), and LDL cholesterol. Intraclass correlations for sibling pairs and interclass correlations for parent-offspring and spouse pairs were estimated for log (CAC score+1) and for the residuals from the 2 regression models to assess familial aggregation.22
To determine the contribution of genes to CAC quantity, the level of a quantitative trait, y, for individual i was modeled as yi=µ+
ßjXij+gi+ei, where µ is the trait mean, Xij is the j-th covariate, and ßj is its regression coefficient. The remaining variables represent the random deviations from µ for individual i that are attributable to additive genetic and residual error effects, respectively. The residual error component includes true random error, measurement error, and any nonadditive genetic components. The effects of gi and ei are assumed to be not correlated and normally distributed with mean zero and variances 
g2 and e2, respectively. Maximum likelihood methods were used to simultaneously estimate the mean and variances as well as the covariate and genetic effects.23 Significance of covariate effects was assessed with a Wald test.24 Heritability was defined as the relative proportion of the residual variance in the quantitative trait explained by additive genetic factors divided by the residual variance after adjustment for covariates. This definition of heritability is the same as that used by others in studies of calcification.13,25 The significance of genetic effects was assessed by comparing twice the difference in natural logarithm likelihoods between a model with genetic effects estimated and a model with these effects constrained to zero.26
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The sex-specific characteristics of the participants are shown in Table 1. The 698 participants were distributed among 302 families. There were 98 families of size 1, 156 of size 2 to 3, 39 of size 4 to 6, 8 of size 7 to 9, and 1 of size 14 individuals. Sixty-one families included just siblings or siblings and at least one spouse of a sibling. Twenty-five families included at least two generations of participants.
|
Table 2 shows associations between risk factors and log (CAC score+1). The association between age and CAC quantity was adjusted for male sex, and the association between male sex and CAC quantity was adjusted for age. All other associations were adjusted for both age and male sex. All of the factors considered, except HDL cholesterol, DBP, and a college education, were positively and significantly associated with CAC quantity. A college education had a negative, significant association with CAC quantity, whereas HDL cholesterol and DBP were not associated with CAC quantity. Age, male sex, fasting glucose level, log (pack-years+1), and LDL cholesterol were the only risk factors shown to have a positive and statistically significant association with CAC quantity in a multivariable model (data not shown). There were no significant interactions among any of these risk factors.
|
The unadjusted and adjusted estimated correlations for siblings, parents and offspring, and spouses are shown in Table 3. After adjusting for covariates, the estimated correlations between siblings and between parents and offspring were higher than the estimated correlation between spouses. These higher correlations in genetically related individuals compared with unrelated individuals (ie, the spouses) are consistent with a genetic basis for variation in CAC quantity.
|
Table 4 presents the estimated components of variance for CAC quantity. All estimates of heritability for CAC quantity were statistically significantly different from zero (P<0.001). Before adjusting for any covariates, the estimate of heritability was 0.435. After adjusting for age and male sex, the estimate of heritability was 0.449, suggesting that genetic factors account for 
0.292 [(1.0-0.350)x0.449] of the total variance in CAC quantity. After further adjustment for additional covariates, the estimate of heritability was 0.418, suggesting that genetic factors account for 0.246 [(1.0-0.412)x0.418] of the total variance in CAC quantity. The estimates after adjusting for covariates are similar because the additional covariates only explain an additional 0.062 of the total variance in CAC quantity beyond the variation explained by age and male sex.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The associations between risk factors and quantity of CAC found here agree with previous reports.10–13 Age, sex, and measures of body size, lipid metabolism, and blood pressure, as well as history of diabetes, smoking, and hypertension, have all been found to be related to quantity of CAC. As shown here and elsewhere,12,13 these factors explain, at most,
40% of the variability in CAC quantity. Only a small amount of variability unexplained by CAD risk factors is due to noise or artifact in EBCT measures of CAC quantity.11 In this study, we report that >40% of the interindividual variation in quantity of CAC not explained by traditional risk factors is attributable to genetic factors. Studies of candidate genes for CAC are limited. Pfohl et al27 reported an association between the insertion/deletion polymorphism of the angiotensin I–converting enzyme gene and CAC detected by intravascular ultrasound in patients with angiographically documented CAD. Apolipoprotein E genotype was found to influence the relationship between risk factors and EBCT-measured CAC presence in ECAC Study participants.28 Ellsworth et al29 reported a significant association in ECAC Study participants between the S128R polymorphism of the E-selectin gene and presence and quantity of EBCT-measured CAC in asymptomatic women 50 years of age or younger after adjusting for CAD risk factors. In the Helsinki Sudden Death Study, a polymorphism within the tumor necrosis factor locus was associated with extent of calcified lesions in coronary arteries.30 In all of these studies, the effects of the genes have been small and no findings have been replicated yet.
Wagenknecht et al13 observed that CAC quantity clustered in 56 families (135 individuals) with 2 or more siblings concordant for type 2 diabetes. The estimated heritability was 0.495 (SE=0.216) after adjusting for age, sex, age by sex interaction, race, and diabetes status. Despite the differences between this and the present study, the estimates of heritability for CAC quantity are remarkably similar. The estimates for heritability reported in the present study also agree well with estimates from the Framingham Heart Study of abdominal aortic calcific deposits assessed from lateral lumbar radiographs.25
Study Limitations
The findings from this study are limited to asymptomatic whites age 45 and older living in Rochester, Minn. Our study participants are similar, in many ways, to others. The prevalence of hypertension (25.3% in women and 31.1% in men) is slightly higher than age-adjusted prevalences for non-Hispanic white women (20.5%) and men (25.2%) 20 years of age.31 In our study, 58.2% of those with hypertension were on medication, whereas nationally, 53.6% are on medication.31 The prevalence of obesity (body mass index 30 kg/m2) was 24.7% in women and 23.4% in men in the present study compared with 23.2% and 20.8% among non-Hispanic white women and men ages 20 to 74 nationally.31 The prevalence of diabetes here (2.5%) was lower than national estimates of 7.3%.31 The proportion of our participants who report that they currently smoke (9.4% of women and 10.7% of men) is substantially lower than national estimates for non-Hispanic whites 18 years of age (23.1% of women and 25.5% of men).31 The higher proportions nationally may reflect the tremendous increase in smoking initiation among younger individuals.31 Finally, the 10-year Framingham risk for our participants ranged from 0.5% to 46%. Only 1.4% of women but 22.2% of the men would be considered high risk with a 10-year Framingham risk 20%.
In the present study, the estimates for heritability may overestimate the genetic contribution because we have not estimated shared environments. All siblings reported living in separate households from one another and from their parents at the time of the study. It is possible that shared environments early in life contribute to the correlations for CAC quantity seen among adult relatives. For the spouses, we cannot separate how much of their correlation is due to shared environments and how much is due to assortative mating for factors related to CAC quantity. We could assume that all the spouse correlation is due to shared environments, which is unlikely, and that the strength of the shared environments between spouses is similar to that among relatives. Under these assumptions, genetic factors would be stronger than shared environmental factors in our study because the estimated spouse correlation is much lower than the corresponding estimate of heritability, especially after adjustment for risk factors.
Conclusions
In conclusion, our findings suggest a substantial genetic component for subclinical coronary atherosclerosis variation as measured by CAC quantity, even after accounting for effects of genes acting through some measured atherosclerosis risk factors. Although the CAC process has a complex pathogenesis that likely is influenced by the interaction of numerous environmental and genetic factors, the evidence for genetic effects suggests it should be possible to localize previously unknown genes that influence CAC quantity. Studies to localize such genes are just beginning.32 These genes may act through other measurable atherosclerosis risk factors or through novel pathways that have not or cannot be measured in vivo. Identification of such genes will provide a better basis for prevention and treatment of subclinical coronary atherosclerosis.
|
Acknowledgments |
|---|
This research was supported in part by a General Clinic Research Center grant from the National Institutes of Health (MO1-RR00585) awarded to Mayo Clinic Rochester and by Grant R01 HL46292 from the National Institutes of Health, Public Health Service. Some of the results of this paper were obtained by using the program package S.A.G.E., which is supported by a US Public Heath Service Resource Grant (1 P41 RR03655) from the National Center for Research Resources.
|
Footnotes |
|---|
Guest editor for this article was Bruce Brundage, MD, Bend Memorial Clinic, Bend, Ore.
Received December 19, 2001; revision received May 4, 2002; accepted May 6, 2002.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Peyser PA. Genetic epidemiology of coronary artery disease. Epidemiol Rev. 1997; 19: 80–90.
2. Lusis AJ. Atherosclerosis. Nature. 2000; 407: 233–241.[CrossRef][Medline] [Order article via Infotrieve]
3. Devereux RB, Alderman MH. Role of preclinical cardiovascular disease in the evolution from risk factor exposure to development of morbid events. Circulation. 1993; 88: 1444–1445.
4. Wexler L, Brundage B, Crouse J, et al. Coronary artery calcification: pathophysiology, epidemiology, imaging methods, and clinical implications. Circulation. 1996; 94: 1175–1192.
5. Rumberger JA, Brundage BH, Rader DJ, et al. Electron beam computed tomographic coronary calcium scanning: a review and guidelines for use in asymptomatic persons. Mayo Clin Proc. 1999; 74: 243–252.[Abstract]
6. Guerci AD, Arad Y, Agatston A. Predictive value of EBCT scanning. Circulation. 1998; 97: 2583–2584.
7. Bielak LF, Rumberger JA, SheedyPFII, et al. Probabilistic model for prediction of angiographically defined obstructive coronary artery disease using electron beam computed tomography calcium score strata. Circulation. 2000; 102: 380–385.
8. Arad Y, Spadaro LA, Goodman K, et al. Prediction of coronary events with electron beam computed tomography. J Am Coll Cardiol. 2000; 36: 1253–1260.
9. Keelan PC, Bielak LF, Ashai K, et al. Long-term prognostic value of coronary calcification detected by electron-beam computed tomography in patients undergoing coronary angiography. Circulation. 2001; 104: 412–417.
10. Wong ND, Kouwabunpat D, Vo AN, et al. Coronary calcium and atherosclerosis by ultrafast computed tomography in asymptomatic men and women: relation to age and risk factors. Am Heart J. 1994; 127: 422–430.[CrossRef][Medline] [Order article via Infotrieve]
11. Maher JE, Raz JA, Bielak LF, et al. Potential of quantity of coronary artery calcification to identify new risk factors for asymptomatic atherosclerosis. Am J Epidemiol. 1996; 144: 943–953.
12. Valdes AM, Wolfe ML, Tate HC, et al. Association of traditional risk factors with coronary calcification in persons with a family history of premature coronary heart disease: the study of the inherited risk of coronary atherosclerosis. J Investig Med. 2001; 49: 353–361.[Medline] [Order article via Infotrieve]
13. Wagenknecht LE, Bowden DW, Carr JJ, et al. Familial aggregation of coronary artery calcium in families with type 2 diabetes. Diabetes. 2001; 50: 861–866.
14. Bielak LF, SheedyPFII, Peyser PA. Coronary artery calcification measured at electron-beam CT: agreement in dual scans runs and change over time. Radiology. 2001; 218: 224–229.
15. Kottke BA, Moll PP, Michels VV, et al. Levels of lipids, lipoproteins, and apolipoproteins in a defined population. Mayo Clin Proc. 1991; 66: 1198–1208.[Medline] [Order article via Infotrieve]
16. Turner ST, Weidman WH, Michels VV, et al. Distribution of sodium-lithium countertransport and blood pressure in Caucasians five to eighty-nine years of age. Hypertension. 1989; 13: 378–391.
17. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993; 269: 3015–3023.
18. Anderson KM, Odell PM, Wilson PW, et al. Cardiovascular disease risk profiles. Am Heart J. 1991; 121: 293–298.[CrossRef][Medline] [Order article via Infotrieve]
19. Reed JE, Rumberger JA, Davitt PJ, et al. System for quantitative analysis of coronary calcification via electron-beam computed tomography. In:Medical Imaging 1994: Physiology and Function from Multidimensional Images. Hoffman EA, Acharya RS, eds.Proc SPIE. 1994;2168:43–53.
20. Agatston AS, Janowitz WR, Hildner FJ, et al. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol. 1990; 15: 827–832.[Abstract]
21. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986; 42: 121–130.[CrossRef][Medline] [Order article via Infotrieve]
22. S. A. G. E. Statistical Analysis for Genetic Epidemiology, Beta 4.0–9. Computer program package available from the Department of Epidemiology and Biostatistics, Rammelkamp Center for Education and Research, MetroHealth Campus, Case Western Reserve University, Cleveland, Ohio. 2001.
23. Almasy L, Blangero J. Multipoint quantitative-trait linkage analysis in general pedigrees. Am J Hum Genet. 1998; 62: 1198–1211.[CrossRef][Medline] [Order article via Infotrieve]
24. Clayton D, Hills M. Statistical Models in Epidemiology. New York, NY: Oxford University Press; 1993.
25. O’Donnell CJ, Chazaro I, Wilson PWF, et al. Heritability of abdominal and thoracic aortic calcific deposits in the Framingham Heart Study. Circulation. 2002; 106: 337–341.
26. Self SA, Liang KY. Asymptotic properties of maximum likelihood estimates and likelihood ratio tests under nonstandard conditions. J Am Stat Assoc. 1987; 82: 605–610.[CrossRef]
27. Pfohl M, Athanasiadis A, Koch M, et al. Insertion/deletion polymorphism of the angiotensin I-converting enzyme gene is associated with coronary artery plaque calcification as assessed by intravascular ultrasound. J Am Coll Cardiol. 1998; 31: 987–991.
28. Kardia SL, Haviland MB, Ferrell RE, et al. The relationship between risk factor levels and presence of coronary artery calcification is dependent on apolipoprotein E genotype. Arterioscler Thromb Vasc Biol. 1999; 19: 427–435.
29. Ellsworth DL, Bielak LF, Turner ST, et al. Gender- and age-dependent relationships between the E-selectin S128R polymorphism and coronary artery calcification. J Mol Med. 2001; 79: 390–398.[CrossRef][Medline] [Order article via Infotrieve]
30. Keso T, Perola M, Laippala P, et al. Polymorphisms within the tumor necrosis factor locus and prevalence of coronary artery disease in middle-aged men. Atherosclerosis. 2001; 154: 691–697.[CrossRef][Medline] [Order article via Infotrieve]
31. American Heart Association. 2002 Heart and Stroke Statistical Update. Dallas, Tex: American Heart Association; 2001. Available at http://216.185.112.5/presenter.jhtml?identifier=3000090. Accessed May 14, 2002.
32. Lange LA, Lange EM, Bielak LF, et al. Autosomal genome-wide scan for coronary artery calcification loci in sibships at high risk for hypertension. Arterioscler Thromb Vasc Biol. 2002; 22: 418–423.
This article has been cited by other articles:
 |
|
 |
|
  F. S. Ertas, T. Hasan, C. Ozdol, S. Gulec, Y. Atmaca, C. Tulunay, H. Karabulut, H. T. Kocum, I. Dincer, K. S. Kose, et al. Relationship Between Angiotensin-Converting Enzyme Gene Polymorphism and Severity of Aortic Valve Calcification Mayo Clin. Proc., August 1, 2007; 82(8): 944 - 948. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. E. Cassidy-Bushrow, L. F. Bielak, P. F. Sheedy II, S. T. Turner, I. J. Kullo, X. Lin, and P. A. Peyser Coronary Artery Calcification Progression Is Heritable Circulation, July 3, 2007; 116(1): 25 - 31. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. K. Arnett, A. E. Baird, R. A. Barkley, C. T. Basson, E. Boerwinkle, S. K. Ganesh, D. M. Herrington, Y. Hong, C. Jaquish, D. A. McDermott, et al. Relevance of Genetics and Genomics for Prevention and Treatment of Cardiovascular Disease: A Scientific Statement From the American Heart Association Council on Epidemiology and Prevention, the Stroke Council, and the Functional Genomics and Translational Biology Interdisciplinary Working Group Circulation, June 5, 2007; 115(22): 2878 - 2901. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Mazzone, P. M. Meyer, G. T. Kondos, M. H. Davidson, S. B. Feinstein, R. B. D'Agostino Sr., A. Perez, and S. M. Haffner Relationship of Traditional and Nontraditional Cardiovascular Risk Factors to Coronary Artery Calcium in Type 2 Diabetes Diabetes, March 1, 2007; 56(3): 849 - 855. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. N. Bella, W. Tang, A. Kraja, D. C. Rao, S. C. Hunt, M. B. Miller, V. Palmieri, M. J. Roman, D. W. Kitzman, A. Oberman, et al. Genome-Wide Linkage Mapping for Valve Calcification Susceptibility Loci in Hypertensive Sibships: The Hypertension Genetic Epidemiology Network Study Hypertension, March 1, 2007; 49(3): 453 - 460. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Post, L. F. Bielak, K. A. Ryan, Y.-C. Cheng, H. Shen, J. A. Rumberger, P. F. Sheedy II, A. R. Shuldiner, P. A. Peyser, and B. D. Mitchell Determinants of Coronary Artery and Aortic Calcification in the Old Order Amish Circulation, February 13, 2007; 115(6): 717 - 724. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Garza, V. M. Montori, J. P. McConnell, V. K. Somers, I. J. Kullo, and F. Lopez-Jimenez Association Between Lipoprotein-Associated Phospholipase A2 and Cardiovascular Disease: A Systematic Review Mayo Clin. Proc., February 1, 2007; 82(2): 159 - 165. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. I. Freedman, D. W. Bowden, M. M. Sale, C. D. Langefeld, and S. S. Rich Genetic Susceptibility Contributes to Renal and Cardiovascular Complications of Type 2 Diabetes Mellitus Hypertension, July 1, 2006; 48(1): 8 - 13. [Full Text] [PDF]
|
|
|
|
|
|
I. J. Kullo, L. F. Bielak, S. T. Turner, P. F. Sheedy II, and P. A. Peyser Aortic Pulse Wave Velocity Is Associated With the Presence and Quantity of Coronary Artery Calcium: A Community-Based Study Hypertension, February 1, 2006; 47(2): 174 - 179. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K P Burdon, C D Langefeld, S R Beck, L E Wagenknecht, J J Carr, B I Freedman, D Herrington, and D W Bowden Association of genes of lipid metabolism with measures of subclinical cardiovascular disease in the Diabetes Heart Study J. Med. Genet., September 1, 2005; 42(9): 720 - 724. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. E. Cassidy, L. F. Bielak, Y. Zhou, P. F. Sheedy II, S. T. Turner, J. F. Breen, P. A. Araoz, I. J. Kullo, X. Lin, and P. A. Peyser Progression of Subclinical Coronary Atherosclerosis: Does Obesity Make a Difference? Circulation, April 19, 2005; 111(15): 1877 - 1882. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Fischer, U. Broeckel, S. Holmer, A. Baessler, C. Hengstenberg, B. Mayer, J. Erdmann, G. Klein, G. Riegger, H. J. Jacob, et al. Distinct Heritable Patterns of Angiographic Coronary Artery Disease in Families With Myocardial Infarction Circulation, February 22, 2005; 111(7): 855 - 862. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. J. Kullo and C. M. Ballantyne Conditional Risk Factors for Atherosclerosis Mayo Clin. Proc., February 1, 2005; 80(2): 219 - 230. [Abstract] [PDF]
|
|
|
|
|
|
C. J. O'Donnell Family History, Subclinical Atherosclerosis, and Coronary Heart Disease Risk: Barriers and Opportunities for the Use of Family History Information in Risk Prediction and Prevention Circulation, October 12, 2004; 110(15): 2074 - 2076. [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. Doherty, L. A. Fitzpatrick, D. Inoue, J.-H. Qiao, M. C. Fishbein, R. C. Detrano, P. K. Shah, and T. B. Rajavashisth Molecular, Endocrine, and Genetic Mechanisms of Arterial Calcification Endocr. Rev., August 1, 2004; 25(4): 629 - 672. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. M. London, C. Marty, S. J. Marchais, A. P. Guerin, F. Metivier, and M.-C. de Vernejoul Arterial Calcifications and Bone Histomorphometry in End-Stage Renal Disease J. Am. Soc. Nephrol., July 1, 2004; 15(7): 1943 - 1951. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. Doherty, L. A. Fitzpatrick, A. Shaheen, T. B. Rajavashisth, and R. C. Detrano Genetic Determinants of Arterial Calcification Associated With Atherosclerosis Mayo Clin. Proc., February 1, 2004; 79(2): 197 - 210. [Abstract] [PDF]
|
|
|
|
 |
|
 J. F. Meschia and T. C. Gerber Editorial Comment--Vascular Thickness and Calcification as Markers of Atherosclerotic Burden Stroke, October 1, 2003; 34(10): 2372 - 2373. [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||